Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3209-3217

  Genovesi, E V ^a   Lamb, L ^a   Medina, I ^a   Taylor, D ^a   Seifer, M ^a,b   Innaimo, S ^a   Colonno, R J ^a   Standring, D N ^a,b   Clark, J M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; DOT HYBRIDIZATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; LIVER BIOPSY; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS INHIBITION;

EID: 0031728652     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3209     Document Type: Article

References (47)

1. Bacon, T. H. 1996. Famciclovir, from the bench to the patient - a comprehensive review of preclinical data. Int. J. Antimicrob. Agents 7:119-134.
2. Bartholomeusz, A., and S. Locarnini. 1997. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int. Antivir. News 5:123-124.
3. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
4. Beasley, R. P., and L. Y. Hwang. 1991. Overview on the epidemiology of hepatocellular carcinoma, p. 532-535. In F. B. Hollinger, S. M. Lemon, and M. Margolis (ed.), Viral hepatitis and liver disease. The Williams & Wilkins Co., Baltimore, Md.
5. Bisacchi, G. S., S. T. Chao, C. Bachard, J. P. Daris, S. F. Innaimo, J. A. Jacobs, O. Kocy, P. Lapointe, A. Martel, Z. Merchant, W. A. Slusarchyk, J. E. Sundeen, M. G. Young, R. J. Colonno, and R. Zahler. 1997. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Bioorg. Med. Chem. Lett. 7: 127-132.
6. Civitico, G. M., and S. A. Locarnini. 1994. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 203:81-89.
7. Cullen, J. M., S. L. Smith, M. G. Davis, S. E. Dunn, C. Botteron, A. Cecchi, D. Linsey, D. Linzey, L. Frick, M. T. Paff, A. Goulding, and K. Biron. 1997. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 41:2076-2082.
8. Davis, M. G., J. E. Wilson, N. A. VanDraanen, W. H. Miller, G. A. Freeman, S. M. Daluge, F. L. Boyd, A. E. Aulabaugh, G. R. Painter, and L. R. Boone. 1996. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antivir. Res. 30:133-145.
9. Dienstag, J. L., R. P. Perillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
10. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y. C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
11. Enriquez, P. M., C. Jung, L. Josephson, and B. C. Tennant. 1995. Conjugation of adenine arabinoside 5′-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity. Bioconjugate Chem. 6:195-202.
12. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
13. Fiume, L., G. Di Stefano, C. Busi, A. Mattioli, M. Rapicetta, R. Giuseppetti, A. R. Ciccaglione, and C. Argenti. 1995. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology 22:1072-1077.
14. Fourel, I., J. M. Cullen, J. Saputelli, C. E. Aldrich, P. Schaffer, D. Averett, J. Pugh, and W. S. Mason. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321-8330.
15. Fourel, I., O. Hantz, K. A. Watanabe, C. Jacquet, B. Chomel, J. J. Fox, and C. Trepo. 1990. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 34:473-475.
16. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36.
17. Habteyesus, A., A. Nordenskjold, C. Bohman, and S. Eriksson. 1991. Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem. Pharmacol. 42:1829-1836.
18. Honkoop, P., and R. A. deMan. 1995. Clinical aspects of nucleoside analogues for chronic hepatitis B. Int. Antivir. News 3:78-80.
19. Ikeda, N., S. Kaneko, A. Shimoda, Y. Inagaki, M. Unoura, M. Okada, Y. Yonekawa, K. Takashashi, and K. Kobayashi. 1994. Efficiency of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus. J. Antimicrob. Chemother. 33:83-89.
20. Innaimo, S. F., M. Seifer, G. S. Bisacchi, D. N. Standring, R. Zahler, and R. J. Colonno. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1444-1448.
21. Jilbert, A. R., T.-T. Wu, J. M. England, D. L. M. Hall, N. Z. Carp, A. P. O'Connell, and W. S. Mason. 1992. Rapid resolution of duck hepatitis B virus occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
22. Kajino, K., A. R. Jilbert, J. Saputelli, C. E. Aldrich, J. Cullen, and W. S. Mason. 1994. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 68: 5792-5803.
23. Kann, M., A. Bischof, and W. H. Gerlich. 1997. In vitro model for the nuclear transport of the hepadnavirus genome. J. Virol. 71:1310-1316.
24. Korba, B. E., B. Baldwin, P. Cote, R. Schinazi, D. Gangemi, J. L. Gerin, and B. C. Tennant. 1997. Effectiveness of combination therapies with 3TC, famciclovir and alpha interferon against woodchuck hepatitis virus replication in chronically-infected woodchucks: model for potential anti-HBV treatments. Antivir. Res. 34:A52.
25. Korba, B. E., and M. R. Boyd. 1996. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemoter. 40:1282-1284.
26. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
27. Korba, B. E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antivir. Res. 15:217-228.
28. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
29. Locarnini, S. A., G. M. Civitico, and J. E. Newbold. 1996. Hepatitis B: new approaches for antiviral chemotherapy. Antivir. Chem. Chemother. 7:53-64.
30. Mason, W. S., J. Cullen, G. Moraleda, J. Saputelli, C. F. Aldrich, D. S. Miller, B. Tennant, L. Frick, D. Averett, L. D. Condreay and A. R. Jilbert. 1998. Lamivudine therapy of WHV-infected woodchucks. Virology 245:18-32.
31. Miller, R., P. Marion, and W. Robinson. 1984. Hepatitis B viral DNA-RNA hybrid molecules in particles from infected liver are converted to viral DNA molecules during an endogenous DNA polymerase reaction. Virology 139: 64-72.
32. Moraleda G., J. Saputelli, C. E. Aldrich, D. Averett, L. Condreay, and W. S. Mason. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:9392-9399.
33. Neven, F., J. Main, P. Honkoop, D. L. Tyrrell, J. Barber, M. T. Sullivan, J. Fevery, R. A. De Man, and H. C. Thomas. 1997. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
34. Ponzetto, A., L. Fiume, B. Forzani, S. Y. Song, C. Busi, A. Mattioli, C. Spinelli, M. Marinelli, A. Smedile, E. Chiaberge, F. Bonino, G. B. Gervasi, M. Rapicetta, and G. Verme. 1991. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepathology 14:16-24.
35. Roggendorf, M., and T. K. Tolle. 1995. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 38:100-112.
36. Seeger, C., J. Summers, and W. S. Mason. 1991. DNA synthesis. Curr. Top. Microbiol. Immunol. 168:41-59.
37. Seifer, M., R. K. Hamatake, R. J. Colono, and D. N. Standring. 1998. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42:3200-3208.
38. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517.
39. Tencza M. G., and J. E. Newbold. 1997. Heterogeneous response for mammalian hepadnavirus infection to acyclovir: drug arrested intermediates of minus strand viral DNA are enveloped and secreted from infected cells as virion-like particles. J. Med. Virol. 51:6-16.
40. Tennant, B. C., J. L. Gerin. 1994. The woodchuck model of hepatitis B virus infection, p. 1455-1466. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schachter, D. A. Shafritz (ed.), The liver: biology and pathobiology. Raven Press, Ltd., New York, N.Y.
41. Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. 1998. Antiviral activity and toxcity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191.
42. Tipples, G. A., M. M. Ma, K. P. Fisher, V. G. Bain, N. M. Kneteman, and D. L. Tyrrell. 1996. Mutations in HBV RNA-dependent polymerase confers resistance to lamivudine in vivo. Hepatology 3:714-717.
43. Tuttleman, J. S., C. Pourcel, and J. Summers. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 47:451-460.
44. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competet HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
45. Wu, T.-T., L. Coates, C. E. Aldrich, J. Summers, and W. S. Mason. 1990. In hepatocytes infected with duck hepatitis B virus, the template or RNA synthesis is amplified by an intracellular conversion pathway. Virology 175: 255-261.
46. Yang, W., W. S. Mason, and J. Summers. 1996. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis B virus-infected livers. J. Virol. 70:4567-4575.
47. Zoulim, F. 1997. Improving hepatitis B virus therapy - new inhibitors of reverse transcriptase. Int. Antivir. News 5:110-112.